Index to volume 65

Author index

A

Aarons L (*see* Gupta et al). 1999;65:672-84
Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. 1999;65:465-72
Abernethy DR (*see* Jones et al). 1999;65:408-12
Abernethy DR (*see* Schulman et al). 1999;65:593-7
Abolfathi Z (*see* Yacobi et al). 1999;65:389-94
Adcock S (*see* Schwartz et al). 1999;65:653-60
Addison RS (*see* Gross et al). 1999;65:395-401
Adedoyin A (*see* Bluhm et al). 1999;65:598-605
Agostoni P (*see* Guazzi et al). 1999;65:319-27
Agúndez JA (*see* Martínez et al). 1999;65:369-76
Albet C (*see* Martínez et al). 1999;65:369-76
Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, Schüttler J. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. 1999;65:630-9
Alemán C (*see* Más et al). 1999;65:439-47
Alisi C (*see* Buemi et al). 1999;65:649-52
Allegra A (*see* Buemi et al). 1999;65:649-52
Andrawis NS (*see* Jones et al). 1999;65:408-12
Aravind MK (*see* Kauffman et al). 1999;65:382-8
Ariyoshi N (*see* Tateishi et al). 1999;65:570-5
Arvieux C (*see* Michelet et al). 1999;65:661-71
Astier A (*see* Sanquer et al). 1999;65:640-8
Atkinson AJ (*see* Shepherd and Atkinson). 1999;65:355-6 (Commentary)
Aweeka FT (*see* Brody et al). 1999;65:21-8
Aziz M (*see* Massien et al). 1999;65:448-59

B

Bachmann KA (*see* Schwartz et al). 1999;65:653-60
Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, Hendrix CW, Flexner C. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. 1999;65:428-38
Barennes H (*see* Pussard et al). 1999;65:500-10
Baron C (*see* Sanquer et al). 1999;65:640-8
Bauer S (*see* Mück et al). 1999;65:251-61
Bazin C (*see* Michelet et al). 1999;65:661-71
Beaver WT (*see* Wideman et al). 1999;65:66-76
Bedarida GV (*see* Chalon et al). 1999;65:58-65
Beerahee M (*see* Hussein et al). 1999;65:1-9
Beglinger C (*see* Drewe et al). 1999;65:413-9
Bellisant E (*see* Michelet et al). 1999;65:661-71
Benítez J (*see* Martínez et al). 1999;65:369-76
Benovic JL (*see* Gros et al). 1999;65:545-51
Berndt A (*see* Scwarz et al). 1999;65:283-290
Bickel U (*see* Heitmann et al). 1999;65:328-35
Bjornsson T (*see* McCrea et al). 1999;65:348-52
Blaschke TF (*see* Chalon et al). 1999;65:58-65
Blaschke TF (*see* Chalon et al). 1999;65:295-303
Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. 1999;65:598-605
Blum RA (*see* Chakraborty et al). 1999;65:304-18
Bochner F (*see* Dyer et al). 1999;65:685-94
Branch RA (*see* Bluhm et al). 1999;65:598-605
Breil M (*see* Sanquer et al). 1999;65:640-8
Bremer F (*see* Tegeder et al). 1999;65:50-7
Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. 1999;65:21-8
Brune K (*see* Tegeder et al). 1999;65:50-7
Brune K (*see* Tegeder et al). 1999;65:357-68
Brune K (*see* Tegeder et al). 1999;65:533-44
Budde K (*see* Mück et al). 1999;65:251-61
Buemi M, Allegra A, Corica F, Ruello A, Alisi C, Pettinato G, Giacobbe MS, Romeo A, Frisina N. Effects of lisinopril administration on blood *bcl*-2 concentrations in patients with immunoglobulin A nephropathy. 1999;65:649-52
Bukowski R (*see* Rakhit et al). 1999;65:615-29
Bulitta J (*see* Kinzig-Schippers et al). 1999;65:262-74

C

Caraco Y (*see* Sviri et al). 1999;65:275-82
Carcas AJ, García-Satué JL, Zapater P, Frías-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. 1999;65:245-50
Carrillo JA (*see* Martínez et al). 1999;65:369-76
Cartier F (*see* Michelet et al). 1999;65:661-71
Carvajal DM (*see* Rakhit et al). 1999;65:615-29
Cassel W (*see* Heitmann et al). 1999;65:328-35
Castaño G (*see* Más et al). 1999;65:439-47
Chakraborty A, Blum RA, Cutler DL, Jusko WJ. Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. 1999;65:304-18
Chalon S, Bedarida GV, Moreno H, Tejura B, Urae A, Hoffman BB, Blaschke TF. Inhibition of angiotensin-converting enzyme in human hand veins. 1999;65:58-65
Chalon S, Moreno H, Hoffman BB, Blaschke TF. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. 1999;65:295-303
Chan CC (*see* Schwartz et al). 1999;65:653-60
Chauvin JP (*see* Michelet et al). 1999;65:661-71
Cheng CL (*see* Huang et al). 1999;65:402-7
Chida M (*see* Tateishi et al). 1999;65:570-5
Chorazyczewski J (*see* Gros et al). 1999;65:545-51
Chuang SK (*see* Huang et al). 1999;65:402-7
Clavier F (*see* Pussard et al). 1999;65:500-10
Cohen RA (*see* Schwartz et al). 1999;65:653-60
Colaizzi JL (*see* Yacobi et al). 1999;65:389-94
Colburn W (*see* Scheffler et al). 1999;65:483-90
Colice G (*see* Hussein et al). 1999;65:1-9
Coresh J (*see* Barditch-Crovo et al). 1999;65:423-38
Corica F (*see* Buemi et al). 1999;65:649-52
Cribb A (*see* McCrea et al). 1999;65:348-52
Cundy KC (*see* Brody et al). 1999;65:21-8
Cutler DL (*see* Chakraborty et al). 1999;65:304-18
Czaja-Bulsa G (*see* Gawrońska-Szklarz et al). 1999;65:562-9

D

Dallaire BK (*see* de Jonge et al). 1999;65:491-9
Dallob A (*see* Ehrich et al). 1999;65:336-47

January, pp. 1-116; February, pp. 117-234; March, pp. 235-354; April, pp. 355-464; May, pp. 465-592; June, pp. 593-716. Index to the ASCPT meeting abstracts is located in the February issue.

Dammeyer J (*see* Kinzig-Schippers et al). 1999;65:262-74
Daouda H (*see* Pussard et al). 1999;65:500-10
Das S (*see* Iyer et al). 1999;65:576-82
Davidson MH (*see* Schwartz et al). 1999;65:653-60
De Jonge MJA, Verweij J, Loos WJ, Dallaire BK, Sparreboom A. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. 1999;65:491-9
De Lepeleire I (*see* Ehrich et al). 1999;65:336-47
Delfraissy JF (*see* Michelet et al). 1999;65:661-71
De Schepper P (*see* Ehrich et al). 1999;65:336-47
Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome. 1999;65:10-20
Dhamane D (*see* Sanquer et al). 1999;65:640-8
Dingemanse J (*see* Albrecht et al). 1999;65:630-9
Di Rienzo A (*see* Iyer et al). 1999;65:576-82
Dobratz D (*see* Schwartz et al). 1999;65:653-60
Dobrinska M (*see* Tobert et al). 1999;65:583 (Letter)
Dohin E (*see* Michelet et al). 1999;65:661-71
Donaldson J (*see* Hussein et al). 1999;65:1-9
Doyle RT (*see* Wideman et al). 1999;65:66-76
Drewe J, Sieber CC, Mottet C, Wullschleger C, Larsen F, Beglinger C. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. 1999;65:413-9
Ducharme MP (*see* Edwards et al). 1999;65:237-44
Dyer KR, Foster DJR, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of holders versus non-holders and concentration-effect relationships. 1999;65:685-94

E

Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz, Watkins P. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein. 1999;65:237-44
Eerle LV (*see* Lima et al). 1999;65:519-25
Egan LJ, Sandborn WJ, Mayes DC, Tremaine WJ, Fauq AH, Lipsky JJ. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. 1999;65:29-39
Egan TD (*see* Hermann et al). 1999;65:511-8
Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. 1999;65:336-47
Ette E (*see* Barditch-Crovo et al). 1999;65:423-38

F

Fauq AH (*see* Egan et al). 1999;65:29-39
Feldman RD (*see* Gros et al). 1999;65:545-51
Fernández J (*see* Más et al). 1999;65:439-47
Fernández L (*see* Más et al). 1999;65:439-47
Ferrante J (*see* Rakhit et al). 1999;65:615-29
Fettner S (*see* Rakhit et al). 1999;65:615-29
Fitzsimmons ME (*see* Edwards et al). 1999;65:237-44
Flexner C (*see* Barditch-Crovo et al). 1999;65:423-38
Flockhart DA (*see* Desta et al). 1999;65:10-20
Flockhart DA (*see* Ko et al). 1999;65:606-14
Foster DJR (*see* Dyer et al). 1999;65:685-94
Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK. Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. 1999;65:473-82
Freeman DJ (*see* Tschen et al). 1999;65:526-32
Frías-Iniesta J (*see* Carcas et al). 1999;65:245-50
Frisina N (*see* Buemi et al). 1999;65:649-52
Fritsche L (*see* Mück et al). 1999;65:251-61
Fuhr U (*see* Kinzig-Schippers et al). 1999;65:262-74
Furukori H (*see* Mihara et al). 1999;65:291-4
Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. *CYP2C19* genotype status and effect of omeprazole on intragastric pH in humans. 1999;65:552-61

G

Gambertoglio JG (*see* Brody et al). 1999;65:21-8
García-Satué JL (*see* Carcas et al). 1999;65:245-50
Gately MK (*see* Rakhit et al). 1999;65:615-29
Gaudreault J (*see* Lalonde et al). 1999;65:40-9
Gawrońska-Szklarz B, Lsuzawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. 1999;65:562-9
Geisslinger G (*see* Albrecht et al). 1999;65:630-9
Geisslinger G (*see* Tegeder et al). 1999;65:50-7
Geisslinger G (*see* Tegeder et al). 1999;65:357-68
Geisslinger G (*see* Tegeder et al). 1999;65:533-44
Gertz BJ (*see* Ehrich et al). 1999;65:336-47
Gertz BJ (*see* Schwartz et al). 1999;65:653-60
Giacobbe MS (*see* Buemi et al). 1999;65:649-52
Gillen L (*see* McCrea et al). 1999;65:348-52
Goh YD (*see* Gross et al). 1999;65:395-401
Golander Y (*see* Yacobi et al). 1999;65:389-94
Goldberg MR (*see* McCrea et al). 1999;65:348-52
Gotschall RR (*see* Abdel-Rahman et al). 1999;65:465-72
Gramatté T (*see* Scwarz et al). 1999;65:283-290
Granic G (*see* Pussard et al). 1999;65:500-10
Grasing K (*see* Schwartz et al). 1999;65:653-60
Gros R, Tan CM, Chorazyczewski J, Kelvin DJ, Benovic JL, Feldman RD. G-protein-coupled receptor kinase expression in hypertension. 1999;65:545-51
Gross AS, Goh YD, Addison RS, Shenfield GM. Influence of grapefruit juice on cisapride pharmacokinetics. 1999;65:395-401
Grote L (*see* Heitmann et al). 1999;65:328-35
Grover R (*see* Hussein et al). 1999;65:1-9
Gruer PJ (*see* Tobert et al). 1999;65:583 (Letter)
Guazzi M, Melzi G, Marenzi GC, Agostoni P. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. 1999;65:319-27
Guntupalli K (*see* Hussein et al). 1999;65:1-9
Gupta SK, Sathyan G, Lindemulder EA, Ho PL, Sheiner LB, Aarons L. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. 1999;65:672-84
Guyene TT (*see* Massien et al). 1999;65:448-59

H

Hall D (*see* Iyer et al). 1999;65:576-82
Hanai H (*see* Furuta et al). 1999;65:552-61
Harris RZ (*see* Freed et al). 1999;65:473-82
Hartlaub U (*see* Heitmann et al). 1999;65:328-35
Hedges J (*see* Schwartz et al). 1999;65:653-60
Heitmann J, Cassel W, Grote L, Bickel U, Hartlaub U, Penzel T, Peter JH. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? 1999;65:328-35
Hendrix CW (*see* Barditch-Crovo et al). 1999;65:423-38
Hering W (*see* Albrecht et al). 1999;65:630-9
Hermann DJ, Egan TD, Muir KT. Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. 1999;65:511-8

Herrero E (*see* Martínez et al). 1999;65:369-76
Hoffman BB (*see* Chalon et al). 1999;65:58-65
Hoffman BB (*see* Chalon et al). 1999;65:295-303
Ho PL (*see* Gupta et al). 1999;65:672-84
Huang J, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. 1999;65:402-7
Humphreys MH (*see* Brody et al). 1999;65:21-8
Hussein Z, Beerahee M, Grover R, Jordan B, Jeffs R, Donaldson J, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. Pharmacokinetics of the nitric oxide synthase inhibitor L-N^G-methylarginine hydrochloride in patients with septic shock. 1999;65:1-9

I

Ihmsen H (*see* Albrecht et al). 1999;65:630-9
Ilnait J (*see* Más et al). 1999;65:439-47
Ilson BE (*see* Freed et al). 1999;65:473-82
Inoue Y (*see* Mihara et al). 1999;65:291-4
Ishizaki T (*see* Furuta et al). 1999;65:552-61
Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. 1999;65:576-82

J

Jang IJ (*see* Ko et al). 1999;65:606-14
Jeffs R (*see* Hussein et al). 1999;65:1-9
Jiang JG (see Wideman et al). 1999;65:66-76
Johne A (*see* Mück et al). 1999;65:251-61
Johnson JA (*see* Lima et al). 1999;65:519-25
Jones DW, Andrawis NS, Abernethy DR. Impaired endothelial-dependent forearm vascular relaxation in black Americans. 1999;65:408-12
Jones TM (*see* Schwartz et al). 1999;65:653-60
Jordan B (*see* Hussein et al). 1999;65:1-9
Jorkasky DK (*see* Freed et al). 1999;65:473-82
Jusko WJ (*see* Chakraborty et al). 1999;65:304-18

K

Kamataki T (*see* Tateishi et al). 1999;65:570-5
Kaneko E (*see* Furuta et al). 1999;65:552-61
Kaneko S (*see* Mihara et al). 1999;65:291-4
Kantola T (*see* Neuvonen et al). 1999;65:583 (Letter reply)
Karhu D (*see* Lalonde et al). 1999;65:40-9
Kauffman RE, Lieh-Lai MW, Uy HG, Aravind MK. Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children. 1999;65:382-8
Kauffman RE (*see* Abdel-Rahman et al). 1999;65:465-72
Kearns GL (*see* Abdel-Rahman et al). 1999;65:465-72
Keffer M (*see* Wideman et al). 1999;65:66-76
Kelm GR (*see* Tegeder et al). 1999;65:357-68
Kelvin DJ (*see* Gros et al). 1999;65:545-51
Kerbusch T (*see* Desta et al). 1999;65:10-20
Kim S (*see* Iyer et al). 1999;65:576-82
Kimura M (*see* Furuta et al). 1999;65:552-61
Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, Bulitta J, Sörgel F. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. 1999;65:262-74
Kirch W (*see* Scwarz et al). 1999;65:283-290
Kivistö KT (*see* Neuvonen et al). 1999;65:583 (Letter reply)
Kivistö KT (*see* Villikka et al). 1999;65:377-81
Kobayashi S (*see* Tateishi et al). 1999;65:570-5
Ko JW, Jang IJ, Shin JG, Nam SK, Shin SG, Flockhart DA. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. 1999;65:606-14
Kondo T (*see* Mihara et al). 1999;65:291-4
Kook KA (*see* Scheffler et al). 1999;65:483-90
Kosuge K (*see* Furuta et al). 1999;65:552-61
Krappweis J (*see* Scwarz et al). 1999;65:283-290
Krebs S (*see* Tegeder et al). 1999;65:533-44
Kuhlmann J (*see* Mück et al). 1999;65:251-61
Kurzawski G (*see* Gawrońska-Szklarz et al). 1999;65:562-9

L

Labedzki A (*see* Kinzig-Schippers et al). 1999;65:262-74
Lai ML (*see* Huang et al). 1999;65:402-7
Lalonde RL, Gaudreault J, Karhu D, Marriott TB. Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. 1999;65:40-9
Lang P (*see* Sanquer et al). 1999;65:640-8
Larsen F (*see* Drewe et al). 1999;65:413-9
LeBel M (*see* Yacobi et al). 1999;65:389-94
Lee CC, Sidani MA, Hogikyan RV, Supiano MA. The effects of ramipril on sympathetic nervous system function in older patients with hypertension. 1999;65:420-7
Leeder JS (*see* Abdel-Rahman et al). 1999;65:465-72
Leiersdorf E (*see* Sviri et al). 1999;65:275-82
Lescay M (*see* Más et al). 1999;65:439-47
Levitt B (*see* Yacobi et al). 1999;65:389-94
Levy M (*see* Sviri et al). 1999;65:275-82
Lieh-Lai MW (*see* Kauffman et al). 1999;65:382-8
Lima JJ, Thomason DB, Mohamed MHN, Eerle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the β_2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. 1999;65:519-25
Lindemulder EA (*see* Gupta et al). 1999;65:672-84
Lipsky JJ (*see* Egan et al). 1999;65:29-39
Lo MW (*see* McCrea et al). 1999;65:348-52
Loos WJ (*see* de Jonge et al). 1999;65:491-9
Lötsch J (*see* Tegeder et al). 1999;65:50-7
Lötsch J (*see* Tegeder et al). 1999;65:357-68
Lötsch J (*see* Tegeder et al). 1999;65:533-44
Lsuzawska-Kutrzeba T (*see* Gawrońska-Szklarz et al). 1999;65:562-9

M

Magram J (*see* Rakhit et al). 1999;65:615-29
Mai I (*see* Mück et al). 1999;65:251-61
Mangold B (*see* Massien et al). 1999;65:448-59
Marenzi GC (*see* Guazzi et al). 1999;65:319-27
Márquez M (*see* Martínez et al). 1999;65:369-76
Marriott TB (*see* Lalonde et al). 1999;65:40-9
Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Oritz JA. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H_2-receptor antagonists. 1999;65:369-76
Más R, Castaño G, Ilnait J, Fernández L, Fernández J, Alemán C, Pontigas V, Lescay M. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. 1999;65:439-47
Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Ménard J. Pharmacodynamic effects of dual neutral endopeptidase–angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. 1999;65:448-59
Masson E (*see* Yacobi et al). 1999;65:389-94
Mayes DC (*see* Egan et al). 1999;65:29-39
McBride K (*see* Schwartz et al). 1999;65:653-60
McCarver DG (*see* Bluhm et al). 1999;65:598-605

McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Speilberg S, Goldberg MR. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. 1999;65:348-52
Mehlisch DR (*see* Ehrich et al). 1999;65:336-47
Mehta R (*see* Yacobi et al). 1999;65:389-94
Meller S (*see* Tegeder et al). 1999;65:357-68
Melzi G (*see* Guazzi et al). 1999;65:319-27
Ménard J (*see* Massien et al). 1999;65:448-59
Menelaou A (*see* Dyer et al). 1999;65:685-94
Michelet C, Bellisant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sebille V, Chauvin JP, Dohin E, Cartier F. Safety and efficacy of retonavir and saquinavir in combination with zidovudine and lamivudine. 1999;65:661-71
Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y. Effects of the *CYP2D6*10* allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. 1999;65:291-4
Mizorogi Y (*see* Tateishi et al). 1999;65:570-5
Mohamed MHN (*see* Lima et al). 1999;65:519-25
Moreno H (*see* Chalon et al). 1999;65:58-65
Moreno H (*see* Chalon et al). 1999;65:295-303
Moritz C (*see* Schwartz et al). 1999;65:653-60
Moros D (*see* Yacobi et al). 1999;65:389-94
Morris E (*see* Wideman et al). 1999;65:66-76
Mortell MA (*see* Iyer et al). 1999;65:576-82
Mottet C (*see* Drewe et al). 1999;65:413-9
Motzer R (*see* Rakhit et al). 1999;65:615-29
Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. 1999;65:251-61
Muir KT (*see* Hermann et al). 1999;65:511-8
Mukhopadhyay S (*see* Schwartz et al). 1999;65:653-60
Muth-Selbach U (*see* Tegeder et al). 1999;65:357-68
Muth-Selbach U (*see* Tegeder et al). 1999;65:533-44

N

Nadeau R (*see* Rakhit et al). 1999;65:615-29
Nagashima U (*see* Mihara et al). 1999;65:291-4
Nam SK (*see* Ko et al). 1999;65:606-14
Neumann F (*see* Tegeder et al). 1999;65:50-7
Neumayer HH (*see* Mück et al). 1999;65:251-61
Neuvonen PJ, Kantola T, Kivistö KT. Calcium channel blocker-simvastatin interaction. 1999;65:583 (Letter reply)
Neuvonen PJ (*see* Villikka et al). 1999;65:377-81
Nishimoto M (*see* Furuta et al). 1999;65:552-61

O

Ochmann K (*see* Mück et al). 1999;65:251-61
Oelkers R (*see* Tegeder et al). 1999;65:357-68
Oertel R (*see* Scwarz et al). 1999;65:283-290
Ohashi K (*see* Furuta et al). 1999;65:552-61
Oritz JA (*see* Martínez et al). 1999;65:369-76
Osborne B (*see* McCrea et al). 1999;65:348-52
Osse M (*see* Pussard et al). 1999;65:500-10
Otani K (*see* Mihara et al). 1999;65:291-4
Oyewumi LK (*see* Tschen et al). 1999;65:526-32

P

Peck CC. A message from the President: The Centennial ASCPT meeting—Come to San Antonio, March 18-20, 1999. 1999;65:80
Penzel T (*see* Heitmann et al). 1999;65:328-35
Peter JH (*see* Heitmann et al). 1999;65:328-35
Pettinato G (*see* Buemi et al). 1999;65:649-52
Pontigas V (*see* Más et al). 1999;65:439-47
Porras A (*see* Ehrich et al). 1999;65:336-47
Presky DH (*see* Rakhit et al). 1999;65:615-29
Proost JH. Do computational results depend on PC processors? 1999;65:460 (Letter)
Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M, Granic G, Verdier F. Quinine disposition in globally malnourished children with cerebral malaria. 1999;65:500-10

R

Raffi F (*see* Michelet et al). 1999;65:661-71
Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J, Gately MK. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. 1999;65:615-29
Ramírez J (*see* Iyer et al). 1999;65:576-82
Ratain MJ (*see* Iyer et al). 1999;65:576-82
Rathore SS (*see* Schulman et al). 1999;65:593-7
Reidenberg MM. New headings for the table of contents. 1999;65:235-6
Renard I (*see* Michelet et al). 1999;65:661-71
Rider MJ (*see* Tschen et al). 1999;65:526-32
Riendeau D (*see* Ehrich et al). 1999;65:336-47
Rocco LE (*see* Barditch-Crovo et al). 1999;65:423-38
Rohde G (*see* Mück et al). 1999;65:251-61
Romeo A (*see* Buemi et al). 1999;65:649-52
Roots I (*see* Mück et al). 1999;65:251-61
Ruello A (*see* Buemi et al). 1999;65:649-52
Ruffault A (*see* Michelet et al). 1999;65:661-71
Rushmore T (*see* McCrea et al). 1999;65:348-52
Rüsing G (*see* Kinzig-Schippers et al). 1999;65:262-74
Rüsing G (*see* Tegeder et al). 1999;65:357-68

S

Sandborn WJ (*see* Egan et al). 1999;65:29-39
Sani AM (*see* Pussard et al). 1999;65:500-10
Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. 1999;65:640-8
Sathyan G (*see* Gupta et al). 1999;65:672-84
Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics. 1999;65:483-90
Schoenfeld P (*see* Brody et al). 1999;65:21-8
Schuetz EG (*see* Edwards et al). 1999;65:237-44
Schuetz JD (*see* Edwards et al). 1999;65:237-44
Schulman KA, Abernethy DR, Rathore SS, Woosley RL. Regulating manufacturer-affiliated communication in the information age. 1999;65:593-7
Schüttler J (*see* Albrecht et al). 1999;65:630-9
Schwartz JI, Chan CC, Mukhopadhyay S, McBride K, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, Davidson MH, Bachmann KA, Gertz BJ. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. 1999;65:653-60
Schwilden H (*see* Albrecht et al). 1999;65:630-9
Scwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans. 1999;65:283-290
Sebille V (*see* Michelet et al). 1999;65:661-71
Seibold JR (*see* Ehrich et al). 1999;65:336-47

Self TH (*see* Lima et al). 1999;65:519-25
Sheiner LB (*see* Gupta et al). 1999;65:672-84
Shenfield GM (*see* Gross et al). 1999;65:395-401
Shepherd AMM, Atkinson AJ. Report from the American Board of Clinical Pharmacology. 1999;65:355-6 (Commentary)
Shin JG (*see* Ko et al). 1999;65:606-14
Shin SG (*see* Ko et al). 1999;65:606-14
Shpizen S (*see* Sviri et al). 1999;65:275-82
Sieber CC (*see* Drewe et al). 1999;65:413-9
Somogyi AA (*see* Dyer et al). 1999;65:685-94
Sörgel F (*see* Kinzig-Schippers et al). 1999;65:262-74
Sörgel F (*see* Tegeder et al). 1999;65:357-68
Sparreboom A (*see* de Jonge et al). 1999;65:491-9
Speilberg S (*see* McCrea et al). 1999;65:348-52
Suzuki A (*see* Mihara et al). 1999;65:291-4
Sviri S, Shpizen S, Leiersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. 1999;65:275-82

T

Takashima M (*see* Furuta et al). 1999;65:552-61
Tan CM (*see* Gros et al). 1999;65:545-51
Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the *CYP2D6* gene in relation to dextromethorphan *O*-demethylation capacity in a Japanese population. 1999;65:570-5
Tegeder I, Lötsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and a steady state. 1999;65:533-44
Tegeder I, Muth-Selbach U, Lötsch J, Rüsing G, Oelkers R, Brune K, Meller S, Kelm GR, Sörgel F, Geisslinger G. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. 1999;65:357-68
Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. 1999;65:50-7
Tejura B (*see* Chalon et al). 1999;65:58-65
Thomason DB (*see* Lima et al). 1999;65:519-25
Thomas SD (*see* Scheffler et al). 1999;65:483-90
Thompson KA (*see* Freed et al). 1999;65:473-82
Tobert JA, Vega JM, Dobrinska M, Gruer PJ. Calcium channel blocker-simvastatin interaction. 1999;65:583 (Letter)
Trapnell CB (*see* Barditch-Crovo et al). 1999;65:423-38
Tremaine WJ (*see* Egan et al). 1999;65:29-39
Tschen AC, Rieder MJ, Oyewumi LK, Freeman DJ. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. 1999;65:526-32

U

Unger S (*see* Mück et al). 1999;65:251-61
Urae A (*see* Chalon et al). 1999;65:58-65
Uy HG (*see* Kauffman et al). 1999;65:382-8

V

Van Hecken A (*see* Ehrich et al). 1999;65:336-47
Vega JM (*see* Tobert et al). 1999;65:583 (Letter)
Verdier F (*see* Pussard et al). 1999;65:500-10
Verweij J (*see* de Jonge et al). 1999;65:491-9
Vesterqvist O (*see* Massien et al). 1999;65:448-59
Villikka K, Kivistö KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondanestron. 1999;65:377-81
Vincent JL (*see* Hussein et al). 1999;65:1-9
von Richter O (*see* Scwarz et al). 1999;65:283-290

W

Waldman S (*see* McCrea et al). 1999;65:348-52
Warbasse LH (*see* Edwards et al). 1999;65:237-44
Watkins P (*see* Edwards et al). 1999;65:237-44
Watson D (*see* Hussein et al). 1999;65:1-9
White JM (*see* Dyer et al). 1999;65:685-94
Wideman GL, Keffer M, Morris E, Doyle RT, Jiang JG, Beaver WT. Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain. 1999;65:66-76
Wilkinson VL (*see* Rakhit et al). 1999;65:615-29
Wilson DE (*see* Freed et al). 1999;65:473-82
Wittreich J (*see* Ehrich et al). 1999;65:336-47
Woosley (*see* Schulman et al). 1999;65:593-7
Woster PM LH (*see* Edwards et al). 1999;65:237-44
Wullschleger C (*see* Drewe et al). 1999;65:413-9

Y

Yacobi A, Zlotnick S, Colaizzi JL, Moros D, Masson E, Abolfathi Z, LeBel M, Mehta R, Golander Y, Levitt B. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine. 1999;65:389-94
Yasuda K (*see* Edwards et al). 1999;65:237-44
Yasui N (*see* Mihara et al). 1999;65:291-4
Yeon MM (*see* Rakhit et al). 1999;65:615-29
Yuan W (*see* Ehrich et al). 1999;65:336-47

Z

Zaccardelli D (*see* Hussein et al). 1999;65:1-9
Zacur HA (*see* Barditch-Crovo et al). 1999;65:423-38
Zaigler M (*see* Kinzig-Schippers et al). 1999;65:262-74
Zapater P (*see* Carcas et al). 1999;65:245-50
Zhao XJ (*see* Furuta et al). 1999;65:552-61
Zlotnick S (*see* Yacobi et al). 1999;65:389-94

Subject index

A

Acetylation
Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors (Bluhm et al). 1999;65:598-605
Relationship between acetylation polymorphism and risk of atopic diseases (Gawrodańska-Szklarz et al). 1999;65:562-9
Acid-base equilibrium
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans (Furuta et al). 1999;65:552-61
Administration, topical
Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration (Tegeder et al). 1999;65:357-68
Adrenergic beta blockers
Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans (Schwarz et al). 1999;65:283-290
Aged
The effects of ramipril on sympathetic nervous system function in older patients with hypertension (Lee et al). 1999;65:420-7
Age factors
The effect of age on the pharmacokinetics and pharmacodynamics of midazolam (Albrecht et al). 1999;65:630-9
Agranulocytosis
The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis (Tschen et al). 1999;65:526-32
Albuterol
Impact of genetic polymorphisms of the β_2-adrenergic receptor on albuterol bronchodilator pharmacodynamics (Lima et al). 1999;65:519-25
Alitretinoin
Alitretinoin (USAN List No. 416). 1999;65:697
Almotriptan malate
Almotriptan malate (USAN List No. 416). 1999;65:697
American Board of Clinical Pharmacy
Report from the American Board of Clinical Pharmacology (Shepherd and Atkinson). 1999;65:355-6 (Commentary)
American Society for Clinical and Pharmacology and Therapeutics
Abstracts of annual meeting. 1999;65:117-234
Election of Officers and Committe Chairpersons for 1999-2000. 1999;65:695
Meeting program. 1999;65:80-116
A message from the Membership Committee Chair (Jones). 1999;65:586-9
A message from the President: The Centennial ASCPT meeting—Come to San Antonio, March 18-20, 1999 (Peck). 1999;65:80
A message from the Scientific Program Committee Chairperson: Submission of abstracts for the 2000 annual meeting (Carruthers). 1999;65:696
Future meeting dates and sites of the ASCPT. 1999;65:696
9-Amnocamptothecin
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva (de Jonge et al). 1999;65:491-9
Amoxicillin sodium
Amoxicillin sodium (USAN List No. 415). 1999;65:592
Amprenavir
Amprenavir (USAN No. 416). 1999;65:702

Analgesia
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model (Ehrich et al). 1999;65:336-47
Analgesics, non-narcotic
Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain (Wideman et al). 1999;65:66-76
Analgesics, opioid
Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain (Wideman et al). 1999;65:66-76
Ancestim
Ancestim (USAN List No. 414). 1999;65:462
Anecortave acetate
Anecortave acetate (USAN List No. 415). 1999;65:592
Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction (Guazzi et al). 1999;65:319-27
Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers (Chalon et al). 1999;65:295-303
Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65
Pharmacodynamic effects of dual neutral endopeptidase–angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans (Massien et al). 1999;65:448-59
Aniline compounds
Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568 (Lalonde et al). 1999;65:40-9
Arzoxifene hydrochloride
Arzoxifene hydrochloride (USAN List No. 416). 1999;65:700
Avasimibe
Avasimibe (USAN List No. 414). 1999;65:462

B

bcl-2. *see* **Proto-oncogene proteins c-bcl-2**
Bexarotene
Bexarotene (USAN List No. 414). 1999;65:462
Biological availability
Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans (Schwarz et al). 1999;65:283-290
Blacks
Impaired endothelial-dependent forearm vascular relaxation in black Americans (Jones et al). 1999;65:408-12
Blood pressure
Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? (Heitmann et al). 1999;65:328-35
Impaired endothelial-dependent forearm vascular relaxation in black Americans (Jones et al). 1999;65:408-12
Bradykinin
Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65
Bronchodilator agents
Impact of genetic polymorphisms of the β_2-adrenergic receptor on albuterol bronchodilator pharmacodynamics (Lima et al). 1999;65:519-25

January, pp. 1-116; February, pp. 117-234; March, pp. 235-354; April, pp. 355-464; May, pp. 465-592; June, pp. 593-716. Index to the ASCPT meeting abstracts is located in the February issue.

C

Calcium
Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568 (Lalonde et al). 1999;65:40-9
Calcium channel blockers
Calcium channel blocker-simvastatin interaction (Tobert et al) (Letter); (Neuvonen et al) (Reply). 1999;65:583
Calfactant
Calfactant (USAN List No. 414). 1999;65:462
Carbamazepine
A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine (Yacobi et al). 1999;65:389-94
Carcinoma, renal cell
Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal (Rakhit et al). 1999;65:615-29
Caspofungin acetate
Caspofungin acetate (USAN List No. 414). 1999;65:462
Cerebral malaria. *see* **Malaria, cerebral**
Cerivastatin
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients (Mück et al). 1999;65:251-61
Child
Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children (Kauffman et al). 1999;65:382-8
Quinine disposition in globally malnourished children with cerebral malaria (Pussard et al). 1999;65:500-10
Chinese
Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999;65:402-7
Cisapride
Influence of grapefruit juice on cisapride pharmacokinetics (Gross et al). 1999;65:395-401
Clarithromycin
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome (Desta et al). 1999;65:10-20
Clinical Pharmacology and Therapeutics
New headings for the table of contents (Riedenberg). 1999;65:235-6
Clinical pharmacy
Report from the American Board of Clinical Pharmacology (Shepherd and Atkinson). 1999;65:355-6 (Commentary)
Clozapine
The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis (Tschen et al). 1999;65:526-32
Colesevelam hydrochloride
Colesevelam hydrochloride (USAN List No. 415). 1999;65:590
Commentaries
Commentaries. 1999;65:355-6
Communication
Regulating manufacturer-affiliated communication in the information age (Schulman et al). 1999;65:593-7
Computers. *see* **Microcomputers**
Continuous ambulatory peritoneal dialysis. *see* **Peritoneal dialysis, continuous ambulatory**
Contraceptives, oral
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (Barditch-Crovo et al). 1999;65:428-38
Coronary disease
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors (Más et al). 1999;65:439-47
Cyclooxygenase. *see* **Prostaglandin endoperoxide synthase**
Cyclosporine
6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein (Edwards et al). 1999;65:237-44
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients (Mück et al). 1999;65:251-61
Cytochrome P450 CYP1A2
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H_2-receptor antagonists (Martínez et al). 1999;65:369-76
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 (Kinzig-Schippers et al). 1999;65:262-74
Cytochrome P450 CYP3A
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H_2-receptor antagonists (Martínez et al). 1999;65:369-76
Cytochrome P450 CYP3A4
6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein (Edwards et al). 1999;65:237-44
Cytochrome P450 CYP2C19
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans (Furuta et al). 1999;65:552-61
Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers (Ko et al). 1999;65:606-14
Cytochrome P450 CYP2D6
Analysis of the *CYP2D6* gene in relation to dextromethorphan *O*-demethylation capacity in a Japanese population (Tateishi et al). 1999;65:570-5
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H_2-receptor antagonists (Martínez et al). 1999;65:369-76
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome (Desta et al). 1999;65:10-20
Effects of the *CYP2D6*10* allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia (Mihara et al). 1999;65:291-4
Investigation of terbinafine as a CYP2D6 inhibitor in vivo (Abdel-Rahman et al). 1999;65:465-72
Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999;65:402-7
Cytosine
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis (Brody et al). 1999;65:21-8

D

Dapsone
Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors (Bluhm et al). 1999;65:598-605
Darbufelone mesylate
Darbufelone mesylate (USAN List No. 416). 1999;65:698
Depreotide
Depreotide (USAN List No. 416). 1999;65:698
Dermatoses. *see* **Skin diseases**
Desloratadine
Desloratadine (USAN List No. 416). 1999;65:699
Dextromethorphan
Analysis of the *CYP2D6* gene in relation to dextromethorphan *O*-demethylation capacity in a Japanese population (Tateishi et al). 1999;65:570-5

Diclofenac
Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and a steady state (Tegeder et al). 1999;65:533-44
Drospireone
Drospireone (USAN List No. 412). 1999;65:79
Drug evaluation
Regulating manufacturer-affiliated communication in the information age (Schulman et al). 1999;65:593-7
Drug interactions
Calcium channel blocker-simvastatin interaction (Tobert et al) (Letter); (Neuvonen et al) (Reply). 1999;65:583
Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers (Chakraborty et al). 1999;65:304-18
Drug metabolism
Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children (Kauffman et al). 1999;65:382-8

E

Ecopipam hydrochloride
Ecopipam hydrochloride (USAN List No. 416). 1999;65:700
Emitefur
Emitefur (USAN List No. 416). 1999;65:701
Enalaprilat
Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65
Enantiomers. *see* **Stereoisomerism**
Endothelium
Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers (Chalon et al). 1999;65:295-303
Eniluracil
Eniluracil (USAN List No. 415). 1999;65:592
Enoxacin
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 (Kinzig-Schippers et al). 1999;65:262-74
Estrogen
Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics (Scheffler et al). 1999;65:483-90

F

FDA. *see* **United States Federal Drug Administration**
Flibanserin
Flibanserin (USAN List No. 416). 1999;65:700
Fodipir
Fodipir (USAN List No. 416). 1999;65:699
Forearm
Impaired endothelial-dependent forearm vascular relaxation in black Americans (Jones et al). 1999;65:408-12
Frovatriptan succinate
Frovatriptan succinate (USAN List No. 416). 1999;65:698

G

Ganaxolone
Ganaxolone (USAN List No. 416). 1999;65:702
Gastric acidity determination
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans (Furuta et al). 1999;65:552-61
Genotype
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans (Furuta et al). 1999;65:552-61
Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999;65:402-7
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174 (McCrea et al). 1999;65:348-52
Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82
Glomerulonephritis, IGA
Effects of lisinopril administration on blood *bcl*-2 concentrations in patients with immunoglobulin A nephropathy (Buemi et al). 1999;65:649-52
G-proteins
G-protein-coupled receptor kinase expression in hypertension (Gros et al). 1999;65:545-51
Grapefruit juice
6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein (Edwards et al). 1999;65:237-44
Influence of grapefruit juice on cisapride pharmacokinetics (Gross et al). 1999;65:395-401
Guest reviewers
Guest reviewers. 1999;65:461

H

Haloperidol
Effects of the *CYP2D6*10* allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia (Mihara et al). 1999;65:291-4
Hand
Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65
Hefilcon A
Hefilcon A (USAN List No. 415). 1999;65:591
Hemodialysis
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis (Brody et al). 1999;65:21-8
Hemofiltration
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration (Tegeder et al). 1999;65:50-7
Hilafilcon A
Hilafilcon A (USAN List No. 415). 1999;65:591
Histamine agonists
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H_2-receptor antagonists (Martínez et al). 1999;65:369-76
Hydrocodone
Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain (Wideman et al). 1999;65:66-76
Hydroxylation
Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors (Bluhm et al). 1999;65:598-605
Hypercholesterolemia
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors (Más et al). 1999;65:439-47
Hypertension
The effects of ramipril on sympathetic nervous system function in older patients with hypertension (Lee et al). 1999;65:420-7
G-protein-coupled receptor kinase expression in hypertension (Gros et al). 1999;65:545-51
Impaired endothelial-dependent forearm vascular relaxation in black Americans (Jones et al). 1999;65:408-12

I

Ibuprofen
Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain (Wideman et al). 1999;65:66-76

Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration (Tegeder et al). 1999;65:357-68

IGA glomerulonephritis. *see* **Glomerulonephritis, IGA**

Immunoglobulin A nephropathy. *see* **Glomerulonephritis, IGA**

Immunosuppressive agents

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease (Egan et al). 1999;65:29-39

Information dissemination *see* **Communication**

Injections, intravenous

The effect of rifampin on the pharmacokinetics of oral and intravenous ondanestron (Villikka et al). 1999;65:377-81

Inosine monophosphate dehydrogenase

Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil (Sanquer et al). 1999;65:640-8

Interleukin-10

Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers (Chakraborty et al). 1999;65:304-18

Interleukin-12

Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal (Rakhit et al). 1999;65:615-29

Irinotecan

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82

Israel

Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82

J

Japanese

Analysis of the *CYP2D6* gene in relation to dextromethorphan *O*-demethylation capacity in a Japanese population (Tateishi et al). 1999;65:570-5

Effects of the *CYP2D6*10* allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia (Mihara et al). 1999;65:291-4

Jews

Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82

K

Ketorolac

Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children (Kauffman et al). 1999;65:382-8

Kidney failure, acute

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration (Tegeder et al). 1999;65:50-7

Kidney failure, chronic

Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis (Brody et al). 1999;65:21-8

Kidney transplantation

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients (Mück et al). 1999;65:251-61

Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil (Sanquer et al). 1999;65:640-8

L

Lamivudine

Safety and efficacy of retonavir and saquinavir in combination with zidovudine and lamivudine (Michelet et al). 1999;65:661-71

Lanreotide

Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers (Drewe et al). 1999;65:413-9

Lansoprazole

Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers (Ko et al). 1999;65:606-14

Left ventricular dysfunction. *see* **Ventricular dysfunction, left**

Letters

Do computational results depend on PC processors? (Proost). 1999;65:460 (Letter)

Lisinopril

Effects of lisinopril administration on blood *bcl*-2 concentrations in patients with immunoglobulin A nephropathy (Buemi et al). 1999;65:649-52

Liver

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82

Lopinavir

Lopinavir (USAN No. 416). 1999;65:701

Losartan

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174 (McCrea et al). 1999;65:348-52

M

Malaria, cerebral

Quinine disposition in globally malnourished children with cerebral malaria (Pussard et al). 1999;65:500-10

Malnourishment. *see* **Nutrition disorders**

Meloxicam

Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and a steady state (Tegeder et al). 1999;65:533-44

Methadone

Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of holders versus nonholders and concentration-effect relationships (Dyer et al). 685-94

Methotrexate

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease (Egan et al). 1999;65:29-39

Metoprolol

Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999;65:402-7

Mice

Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal (Rakhit et al). 1999;65:615-29

Microcomputers

Do computational results depend on PC processors? (Proost). 1999;65:460 (Letter)

Microdialysis

Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration (Tegeder et al). 1999;65:357-68

Midazolam

The effect of age on the pharmacokinetics and pharmacodynamics of midazolam (Albrecht et al). 1999;65:630-9

Modafinil

Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? (Heitmann et al). 1999;65:328-35

Muscle tonus
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone (Freed et al). 1999;65:473-82
Mycophenolate mofetil
Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil (Sanquer et al). 1999;65:640-8

N

Nitric-oxide synthase
Pharmacokinetics of the nitric oxide synthase inhibitor L-N^G-methylarginine hydrochloride in patients with septic shock (Hussein et al). 1999;65:1-9
Nutrition disorders
Quinine disposition in globally malnourished children with cerebral malaria (Pussard et al). 1999;65:500-10

O

omega-N-methylarginine
Pharmacokinetics of the nitric oxide synthase inhibitor L-N^G-methylarginine hydrochloride in patients with septic shock (Hussein et al). 1999;65:1-9
Omeprazole
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans (Furuta et al). 1999;65:552-61
Ondanestron
The effect of rifampin on the pharmacokinetics of oral and intravenous ondanestron (Villikka et al). 1999;65:377-81
Oral contraceptives. *see* **Contraceptives, oral**
Orange juice
6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein (Edwards et al). 1999;65:237-44
Oxaliplatin
Oxaliplatin (USAN No. 416). 1999;65:701
Oxybutynin
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships (Gupta et al). 1999;65:672-84

P

Pain
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model (Ehrich et al). 1999;65:336-47
Pain, postoperative
Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain (Wideman et al). 1999;65:66-76
Pediatrics. *see* **Child**
Pefloxacin
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 (Kinzig-Schippers et al). 1999;65:262-74
Peritoneal dialysis, continuous ambulatory
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis (Brody et al). 1999;65:21-8
P-glycoprotein
6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, P-glycoprotein (Edwards et al). 1999;65:237-44
Phenotype
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174 (McCrea et al). 1999;65:348-52
Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82
Pimozide
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome (Desta et al). 1999;65:10-20
Plasma
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva (de Jonge et al). 1999;65:491-9
Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of holders versus nonholders and concentration-effect relationships (Dyer et al). 685-94
Pleconaril
Pleconaril (USAN List No. 412). 1999;65:79
Pneumonia
Tobramycin penetration into epithelial lining fluid of patients with pneumonia (Carcas et al). 1999;65:245-50
Policosanol
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors (Más et al). 1999;65:439-47
Polymorphisms
Impact of genetic polymorphisms of the β_2-adrenergic receptor on albuterol bronchodilator pharmacodynamics (Lima et al). 1999;65:519-25
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82
Relationship between acetylation polymorphism and risk of atopic diseases (Gawrodańska-Szklarz et al). 1999;65:562-9
Population studies
Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population (Sviri et al). 1999;65:275-82
Prednisone
Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers (Chakraborty et al). 1999;65:304-18
Pregabalin
Pregabalin (USAN List No. 412). 1999;65:78
Progesterone
Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics (Scheffler et al). 1999;65:483-90
Prostaglandin endoperoxide synthase
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model (Ehrich et al). 1999;65:336-47
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans (Schwartz et al). 1999;65:653-60
Protein kinases
G-protein-coupled receptor kinase expression in hypertension (Gros et al). 1999;65:545-51
Proto-oncogene proteins c-bcl-2
Effects of lisinopril administration on blood *bcl*-2 concentrations in patients with immunoglobulin A nephropathy (Buemi et al). 1999;65:649-52
Pulmonary gas exchange
Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction (Guazzi et al). 1999;65:319-27

Q

Quinine
Quinine disposition in globally malnourished children with cerebral malaria (Pussard et al). 1999;65:500-10

R

Ramipril
The effects of ramipril on sympathetic nervous system function in older patients with hypertension (Lee et al). 1999;65:420-7
Receptors, adrenergic, beta
Impact of genetic polymorphisms of the β_2-adrenergic receptor on albuterol bronchodilator pharmacodynamics (Lima et al). 1999; 65:519-25
Receptors, endothelin
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone (Freed et al). 1999;65:473-82
Remifentanil
Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics (Hermann et al). 1999;65:511-8
Renal artery
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone (Freed et al). 1999;65:473-82
Renal cell carcinoma. *see* **Carcinoma, renal cell**
Retonavir
Safety and efficacy of retonavir and saquinavir in combination with zidovudine and lamivudine (Michelet et al). 1999;65:661-71
Retroviridae
Safety and efficacy of retonavir and saquinavir in combination with zidovudine and lamivudine (Michelet et al). 1999;65:661-71
Rifabutin
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (Barditch-Crovo et al). 1999;65:428-38
Rifalazil
Rifalazil (USAN List No. 412). 1999;65:78
Rifampin
The effect of rifampin on the pharmacokinetics of oral and intravenous ondanestron (Villikka et al). 1999;65:377-81
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (Barditch-Crovo et al). 1999;65:428-38
Risk factors
Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors (Bluhm et al). 1999;65:598-605
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors (Más et al). 1999;65:439-47
Rofecoxib
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model (Ehrich et al). 1999;65:336-47
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans (Schwartz et al). 1999;65:653-60
Rofecoxib (USAN List No. 415). 1999;65:590

S

Saliva
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva (de Jonge et al). 1999;65:491-9
SB 209670
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone (Freed et al). 1999;65:473-82
Schizophrenia
Effects of the *CYP2D6*10* allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia (Mihara et al). 1999;65:291-4
Shock, septic
Pharmacokinetics of the nitric oxide synthase inhibitor L-N^G-methylarginine hydrochloride in patients with septic shock (Hussein et al). 1999;65:1-9
Simvastatin
Calcium channel blocker-simvastatin interaction (Tobert et al) (Letter); (Neuvonen et al) (Reply). 1999;65:583
Skin diseases
Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors (Bluhm et al). 1999;65:598-605
Sleep apnea syndromes
Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? (Heitmann et al). 1999;65:328-35
Smoking
Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers (Chalon et al). 1999;65:295-303
SN-38
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism (Iyer et al). 1999;65:576-82
Somatostatin
Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers (Drewe et al). 1999;65:413-9
Stereoisomerism
Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children (Kauffman et al). 1999;65:382-8
Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes (Huang et al). 1999;65:402-7
Sympathetic nervous system
The effects of ramipril on sympathetic nervous system function in older patients with hypertension (Lee et al). 1999;65:420-7

T

Talinolol
Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans (Schwarz et al). 1999;65:283-290
Technetium Tc 99m apcitide
Technetium Tc 99m apcitide (USAN List No. 414). 1999;65:462
Terbinafine
Investigation of terbinafine as a CYP2D6 inhibitor in vivo (Abdel-Rahman et al). 1999;65:465-72
Thalidomide
Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics (Scheffler et al). 1999;65:483-90
Theophylline
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers (Ko et al). 1999;65:606-14
Therapeutic equivalency
A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine (Yacobi et al). 1999;65:389-94
Therapeutic index
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships (Gupta et al). 1999;65:672-84
Thienamycins
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration (Tegeder et al). 1999;65:50-7
Thromboxane
Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and a steady state (Tegeder et al). 1999;65:533-44
Tipranavir disodium
Tiprenavir disodium (USAN List No. 416). 1999;65:702

Tobramycin
Tobramycin penetration into epithelial lining fluid of patients with pneumonia (Carcas et al). 1999;65:245-50
Tolterodine
Tolterodine (USAN List No. 412). 1999;65:79

U

United States Adopted Names Council
USAN Council. 1999;65:77-9, 353-4, 462-4, 590-2, 697-702
United States Federal Drug Administration
Regulating manufacturer-affiliated communication in the information age (Schulman et al). 1999;65:593-7

V

Valganciclovir hydrochloride
Valganciclovir hydrochloride (USAN List No. 412). 1999;65:77
Veins
Inhibition of angiotensin-converting enzyme in human hand veins (Chalon et al). 1999;65:58-65
Ventricular dysfunction, left
Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction (Guazzi et al). 1999;65:319-27
Verapamil
Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans (Schwarz et al). 1999;65:283-290

Z

Zidovudine
Safety and efficacy of retonavir and saquinavir in combination with zidovudine and lamivudine (Michelet et al). 1999;65:661-71